This paper is only available as a PDF. To read, Please Download here.
Abstract
Contraceptive vaginal rings (CVRs) with approximate daily release rates of 250 to
290 μg of levonorgestrel and 150 to 180 μg of estradiol were manufactured in a shell
design, with outside diameters of 50 mm or 58 mm. The rings were studied for contraceptive
effectiveness and acceptability in multicentered trials involving 1,103 ring users.
A comparison group of 533 women using the oral contraceptive, Nordette
∗Nordette is a registered trademark of Wyeth-Pharma, Munster, WeSt Germany.
, was studied simultaneously. Both first and all segment 1-year gross pregnancy rates
among CVR users were less than 3 per 100, approximately the same as the pregnancy
rates observed among users of Nordette. Continuation at 1 year was 50 per 100 users
of the ring (all segments). This rate was significantly higher than or equal to the
rate observed among the users of Nordette, depending upon the analytical treatment
of subjects lost-to-follow-up. The profile of terminations was similar for the users
of the 2 sizes of rings but differed from that of the Nordette acceptors. Gross l-year
rates of termination for medical reasons ranged from 25 to 29 per 100 for the 3 regimens.
Ring users were more likely to terminate for vaginal problems and pill users for headache,
nausea and associated reasons. Problems relating to use of the regimen accounted for
a significantly higher discontinuation rate among CVR than among Nordette users. These
trials indicate that CVRs of this design are as effective in use and have continuation
rates equal to and possibly superior to Nordette under the same study conditions.To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to ContraceptionAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Clinical performance and endocrine profiles with contraceptive vaginal rings containing a combination of estradiol and levonorgestrel.Amer. J. Obstet. Gynecol. 1978; 130: 55-62
- A multicenter study of levonorgestrel-estradiol contraceptive vaginal rings. II. Subjective and objective measures of effects. An international comparative trial.Contraception. 1981; 24: 359-376
- The effect on lipids and lipoproteins of a contraceptive vaginal ring containing levonorgestrel and estradiol.Contraception. 1981; 24: 429-449
Åhrén, T., Lithell, H., Victor, A., Vessby, B. and Johansson, E.D.B.: Serum lipoprotein and apolipoprotein changes during treatment with a contraceptive ring containing levonorgestrel and estradiol. Contraception (Submitted for publication).
- Lipoprotein patterns in women in Santo Domingo using a levonorgestrel/estradiol contraceptive ring.Contraception. 1981; 24: 469-480
Article info
Publication history
Accepted:
September 15,
1981
Received:
August 11,
1981
Identification
Copyright
© 1981 Published by Elsevier Inc.
